focus -WSS

focus

author：fashion 2025-08-23 08:54:37 - browse：15

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Why depression after traumatic brain injury is distinct

WSS

How many hemophilia patients actually want gene therapy?

The science behind Janet Jackson's pregnancy at 49

President Biden's budget: Here's what you might have missed

The strategy behind pharma's lawsuits over drug pricing reform

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Donald Trump's relentless attacks on special counsel Jack Smith

leisure time

focus

focus

How to save PrEP access — and even expand it

President Biden's budget: Here's what you might have missed

Sports medicine is finally prioritizing gender equality

New guidelines on severe brain injury complicate already difficult decisions

Medicare details structure of new drug price negotiation program

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

BioMarin wins approval for gene therapy to treat hemophilia A

Boston's new lab space is opening empty

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

With FDA staff opposed to Sarepta therapy, top official intervened

knowledge

EPA limits use of carcinogenic gas for sterilizing medical devices

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

UCLA team creates talking throat patch for voice disorders

Medicare coverage of Wegovy, once blocked, now looks possible

Boston's new lab space is opening empty

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

focus

knowledge

focus

hotspot